# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

# B Applicant

# C Proprietary and Established Names

Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test Kit

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LSR</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3830 -Treponema PallidumTreponemal Test Reagents</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission: To obtain a substantial equivalence determination and FDA clearance for a new device.   
B Measurand: Anti-Borrelia burgdorferi IgG antibodies   
C Type of Test: Manual ELISA

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test Kit is intended as a qualitative presumptive (first-step) test for the detection of IgG antibodies to $B$ . burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection. Positive and equivocal results must be supplemented by testing with a second-step Western blot assay.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements: None

IV Device/System Characteristics:

A Device Description: During the test procedure, antibodies to $B$ . burgdorferi (sensu stricto) if present in the human serum sample will bind to the antigens coated onto the wells forming antigen-antibody complexes. Excess antibodies are removed by washing. A conjugate of goat anti-human IgG antibodies conjugated with horseradish peroxidase is then added, which binds to the antigen- antibody complexes. Excess conjugate is removed by washing. This is followed by the addition of a chromogenic substrate, tetramethylbenzidine (TMB). If specific antibodies to the antigen are present in the patients’ serum, a blue color will develop. The enzymatic reaction is then stopped with a stopping solution causing the contents of the well to turn yellow. The wells are read photometrically with a microplate reader at $4 5 0 \mathrm { n m }$ .

The antigens used in the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test kit is a combination of B. burgdorferi sensu stricto strain B31 lysate, B. burgdorferi sensu stricto strain 2591 lysate, and a recombinant VlsE protein from $B .$ . burgdorferi sensu stricto strain B31 grown in $E .$ . coli SURE2 cells.

B Principle of Operation: ELISA

V Substantial Equivalence Information:

A Predicate Device Name(s): Mardx Lyme Disease EIA (IgG) Test System   
B Predicate 510(k) Number(s): K894224   
C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K200025</td><td rowspan=1 colspan=1>K894224</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>Gold Standard DiagnosticsBorrelia burgdorferiIgG ELISA Test Kit</td><td rowspan=1 colspan=1>Trinity Biotech MarDxBorrelia burgdorferi EIA IgGTest Kit</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristicSimilarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indicationsfor Use</td><td rowspan=1 colspan=1>The Gold StandardDiagnostics Borreliaburgdorferi IgG ELISATest Kit is intended as aqualitative presumptive(first-step) test for thedetection of IgG antibodiesto B. burgdorferi sensustricto in human serumfrom symptomatic patientsor people suspected ofinfection. Positive andequivocal results must besupplemented by testingwith a second-step Westernblot assay.</td><td rowspan=1 colspan=1>Trinity Biotech MarDxBorrelia burgdorferi EIAIgG Test System is aqualitative test intended foruse in the presumptivedetection of human IgGantibodies to Borreliaburgdorferi in human serum.This EIA system should beused to test serum frompatients with a history andsymptoms of infection withB. burgdorferi. All positiveand equivocal specimensshould be retested with ahighly specific, second-tiertest such as Western blot.Positive second-tier resultsare supportive evidence ofinfection with B. burgdorferi.The diagnosis of Lymedisease should be made basedon history and symptoms(such as erythema migrans),and other laboratory data, inaddition to the presence ofantibodies to B. burgdorferi.Negative results (either firstor second- tier) should not beused to exclude Lymedisease.</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristicDifferences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Antigens</td><td rowspan=1 colspan=1>B. burgdorferi B31 strain,B. burgdorferi 2591 strain,B. burgdorferi recombinantVlsE protein from B31strain</td><td rowspan=1 colspan=1>B. burgdorferi B31 strain</td></tr></table>

# VI Standards/Guidance Documents Referenced:

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

Precision: To determine the precision of the Borrelia burgdorferi IgG ELISA Test, a withinlab precision study was conducted. A precision panel consisting of a negative sample, a high negative sample, a low positive sample, and a moderate positive sample, along with the kit controls, was tested in-house. The sample panel was masked and randomized. Each of the panel members was tested in duplicate, twice per day, for 12 days. The results are summarized in the following table:

Table 1: Precision Study   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanUnits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Between-Run</td><td rowspan=1 colspan=1>Between-Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>ModeratePositive</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>20.3</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.488</td><td rowspan=1 colspan=1>1.312</td><td rowspan=1 colspan=1>1.257</td><td rowspan=1 colspan=1>1.439</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>7.1%</td></tr><tr><td rowspan=2 colspan=1>LowPositive</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>11.5</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.845</td><td rowspan=1 colspan=1>0.718</td><td rowspan=1 colspan=1>0.718</td><td rowspan=1 colspan=1>0.816</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>7.1%</td></tr><tr><td rowspan=2 colspan=1>HighNegative</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>8.3</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.880</td><td rowspan=1 colspan=1>0.646</td><td rowspan=1 colspan=1>0.615</td><td rowspan=1 colspan=1>0.857</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>10.6%</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>10.4%</td></tr><tr><td rowspan=2 colspan=1>Negative</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>0.8</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>0.076</td><td rowspan=1 colspan=1>0.113</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>14.2%</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>10.0%</td><td rowspan=1 colspan=1>14.8%</td></tr><tr><td rowspan=2 colspan=1>PositiveControl</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>17.2</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.947</td><td rowspan=1 colspan=1>0.649</td><td rowspan=1 colspan=1>0.739</td><td rowspan=1 colspan=1>.932</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>5.4%</td></tr><tr><td rowspan=2 colspan=1>CutoffControl</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>10.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.241</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>0.285</td><td rowspan=1 colspan=1>0.264</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=2 colspan=1>NegativeControl</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>0.4</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.424</td><td rowspan=1 colspan=1>0.144</td><td rowspan=1 colspan=1>0.051</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>12.9%</td><td rowspan=1 colspan=1>10.6%</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>12.7%</td></tr></table>

Reproducibility: A reproducibility panel consisting of a negative sample, a high negative sample, a low positive sample, and a moderate positive sample, along with the kit controls, was tested at three different sites. The sample panel was masked and randomized. Each of the panel members was tested in triplicate, twice per day, for five days. The Within-Run, Between-Run, Between-Days, and Between-Sites Standard Deviation and Coefficients of Variation (CV) were calculated. The sample panel was masked and randomized. The results are summarized in the following table:

Table 2: Reproducibility Study   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanUnits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Between-Run</td><td rowspan=1 colspan=1>Between-Day</td><td rowspan=1 colspan=1>Between-Site</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>ModeratePositive</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>21.0</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.54</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>1.29</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=2 colspan=1>LowPositive</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>13.7</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>1.28</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>9.1%</td><td rowspan=1 colspan=1>9.3%</td></tr><tr><td rowspan=2 colspan=1>HighNegative</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>6.6</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>0.67</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>11.7%</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>10.3%</td><td rowspan=1 colspan=1>10.2%</td></tr><tr><td rowspan=2 colspan=1>Negative</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>3.0</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.55</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>21.1%</td><td rowspan=1 colspan=1>18.7%</td><td rowspan=1 colspan=1>16.4%</td><td rowspan=1 colspan=1>18.8%</td><td rowspan=1 colspan=1>18.3%</td></tr><tr><td rowspan=2 colspan=1>PositiveControl</td><td rowspan=2 colspan=1>30</td><td rowspan=2 colspan=1>19.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.65</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>0.62</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=2 colspan=1>CutoffControl</td><td rowspan=2 colspan=1>60</td><td rowspan=2 colspan=1>10.0</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.22</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=2 colspan=1>NegativeControl</td><td rowspan=2 colspan=1>30</td><td rowspan=2 colspan=1>0.5</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>9.5%</td><td rowspan=1 colspan=1>9.6%</td></tr></table>

2. Linearity: N/A

# 3. Analytical Specificity/Interference:

The analytical specificity was determined by testing 208 asymptomatic individuals’ samples from endemic and non-endemic regions. The Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test results are summarized in the following table:

Table 3: Analytical Specificity   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Number of Samples</td><td rowspan=1 colspan=1>NumberPositive/Equivocal</td><td rowspan=1 colspan=1>Analytical Specificity</td></tr><tr><td rowspan=1 colspan=1>Endemic Region</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>96.1%</td></tr><tr><td rowspan=1 colspan=1>Non-endemic Region</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Cross Reactivity: A study using 377 samples was conducted to evaluate potential cross reactivity from different infections and disease conditions. The samples were obtained from serum vendors who confirmed their positivity for each respective marker or clinical diagnosis. The samples were tested on the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test. The results are summarized in the following table:

Table 4: Cross Reactivity   

<table><tr><td colspan="1" rowspan="1">Infection / Diagnosis</td><td colspan="1" rowspan="1">Number ofSera Tested</td><td colspan="1" rowspan="1"># Positive / (%)</td></tr><tr><td colspan="1" rowspan="1">Tick-borne Relapsing Fever IgG</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Treponemal Infections (TPPA)</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Rickettsiosis IgG</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">6 / (24%)</td></tr><tr><td colspan="1" rowspan="1">Ehrlichiosis IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2 / (20%)</td></tr><tr><td colspan="1" rowspan="1">Babesiosis IgG</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">H. pylori IgG</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Parvovirus B19 IgG</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Influenza A&amp;B IgG</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 /(0%)</td></tr><tr><td colspan="1" rowspan="1">Epstein-Barr Virus IgG</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">1 /(3%)</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus IgG</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">0 /(0%)</td></tr><tr><td colspan="1" rowspan="1">Herpes Simplex Virus IgG</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Varicella Zoster Virus</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">1 / (6%)</td></tr><tr><td colspan="1" rowspan="1">Fibromyalgia</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 /(0%)</td></tr><tr><td colspan="1" rowspan="1">Autoimmune Disease</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Multiple Sclerosis</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">0 / (0%)</td></tr><tr><td colspan="1" rowspan="1">Severe Periodontitis</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">0 / (0%)</td></tr></table>

Interfering Substances: The effect of potential interfering substances on samples using the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G }$ ELISA Test was evaluated. Three samples, a high negative, an equivocal and a low positive were spiked with high levels of interferants and were tested along with serum without spiked interferants. The recommended concentrations from the guideline “Interference Testing in Clinical Chemistry” EP07-A3 from the Clinical and Laboratory Standards Institute were used. The tested substances did not affect the performance of the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test.

Table 5: Interfering Substances   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Interference</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>60 mg/ml</td><td rowspan=1 colspan=1>None detected</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>0.4 mg/ml</td><td rowspan=1 colspan=1>None detected</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>4.0 mg/ml</td><td rowspan=1 colspan=1>None detected</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>10 mg/ml</td><td rowspan=1 colspan=1>None detected</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>15 mg/ml</td><td rowspan=1 colspan=1>None detected</td></tr></table>

4. Assay Reportable Range: N/A

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): N/A

6. Detection Limit: N/A

7. Assay Cut-Off:

The cutoff was determined by testing a total of 210 normal sera which consisted of 105 sera from an endemic region of Lyme disease and 105 sera from a non-endemic region of Lyme disease. The mean plus two standard deviations was used to determine the assay cutoff. A known positive sample was then diluted to produce a ready to use cutoff control. An additional 194 samples consisting of 114 samples from different phases of Lyme disease, 8 negative healthy samples, 72 negative Lyme disease samples but do have other diseases that may cause serologic cross-reactivity, were tested. A receiver operating characteristics (ROC)

analysis was performed to evaluate the performance of the assay and confirm that the chosen cutoff provided the best compromise between sensitivity and specificity.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

Comparison studies were conducted at three sites (one internal and two external reference laboratories) using prospective samples submitted for Lyme serology testing. 523 serum samples were tested on both the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test and on the predicate $B .$ . burgdorferi IgG ELISA Test. The results are summarized in the following table:

Table 6: Method Comparison   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Predicate IgG ELISA</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Gold Standard Diagnostics</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=2 colspan=1>Borrelia burgdorferi IgGELISA Test Kit</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>460</td><td rowspan=1 colspan=1>466</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>462</td><td rowspan=1 colspan=1>523</td></tr></table>

\*Equivocal samples counted as positive

Positive percent agreement $= 9 0 . 2 \%$ (55/61) 95% CI $( 7 9 . 8 \% - 9 6 . 3 \% )$ Negative percent agreement $= 9 9 . 6 \%$ (460/462) 95% CI (98.5% - 99.9%)

Second Tier Testing: All positive and equivocal samples by the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test and by the Predicate IgG ELISA were tested by an FDA cleared IgG Western blot assay. The results are summarized in the following table:

Table 7: Comparison by Second Tier Testing   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Tier 1 Positive orEquivocal</td><td rowspan=1 colspan=1>IgG BlotPositive</td><td rowspan=1 colspan=1>IgG BlotNegative</td></tr><tr><td rowspan=1 colspan=1>Predicate IgG ELISA</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Gold StandardDiagnostics Borreliaburgdorferi IgG ELISATest Kit</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>Predicate IgG ELISA+Gold StandardDiagnostics Borreliaburgdorferi IgG ELISATest Kit</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>18</td></tr></table>

<table><tr><td colspan="3">2nd Tier Percent Agreement</td></tr><tr><td>2nd Tier PPA (95% CI)</td><td>100% (92.2% - 100%)</td><td>37/37</td></tr></table>

2. Matrix Comparison: N/A

# C Clinical Studies:

# 1. Clinical Sensitivity:

A sensitivity study was performed on 114 clinically characterized samples. The samples encompass early, disseminated, and late stages of Lyme disease. The samples were tested on both the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test and on the predicate B. burgdorferi IgG ELISA Test. The results are summarized in the following table:

Table 8: Clinical Sensitivity   

<table><tr><td rowspan=1 colspan=1>Disease Stage</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Gold StandardDiagnostics Borreliaburgdorferi IgG ELISATest Kit</td><td rowspan=1 colspan=1>PredicateIgG ELISA</td></tr><tr><td rowspan=1 colspan=1>Early</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>46.6% (27/58)</td><td rowspan=1 colspan=1>27.6% (16/58)</td></tr><tr><td rowspan=1 colspan=1>Disseminated</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>82.4% (14/17)</td><td rowspan=1 colspan=1>52.9% (9/17)</td></tr><tr><td rowspan=1 colspan=1>Late</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>97.4% (38/39)</td><td rowspan=1 colspan=1>97.4% (38/39)</td></tr></table>

CDC Panel: A panel of 280 positive and negative specimens from the Centers of Disease Control (CDC) for Lyme disease detection was tested on both the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G }$ ELISA Test and on the predicate device. The results are presented to convey further information on the performance of the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test with a masked characterized serum panel. This does not imply an endorsement of the assay by the CDC. The results are summarized in the following table:

Table 9: CDC Panel Testing   

<table><tr><td rowspan=2 colspan=1>Disease Stage</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Gold Standard DiagnosticsBorrelia burgdorferi IgGELISA Test Kit</td><td rowspan=1 colspan=2>PredicateIgG ELISA</td></tr><tr><td rowspan=1 colspan=1>Positive orEquivocal</td><td rowspan=1 colspan=1>Agreement withClinical Diagnosis</td><td rowspan=1 colspan=1>Positive orEquivocal</td><td rowspan=1 colspan=1>Agreement withClinical Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Healthy</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99.0%</td></tr><tr><td rowspan=1 colspan=1>Early Lyme</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>68.3%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>35.0%</td></tr><tr><td rowspan=1 colspan=1>Cardiac Lyme</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Neurological Lyme</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>85.7%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>42.9%</td></tr><tr><td rowspan=1 colspan=1>Late</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Look-alike Disease</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>87.8%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>88.9%</td></tr></table>

2. Clinical Specificity: N/A

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): N/A

D Clinical Cut-Off: N/A

# E Expected Values/Reference Range:

The range of values and positivity rate among different studies and population for the Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test are as follows:

Table 10: Expected Values   

<table><tr><td rowspan=2 colspan=1>Population</td><td rowspan=2 colspan=1># Samples</td><td rowspan=1 colspan=3>Unit Results</td><td rowspan=1 colspan=2>Qualitative Results</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Std.Dev.</td><td rowspan=1 colspan=1>#Positive/Equivocal</td><td rowspan=1 colspan=1>%Positive/Equivocal</td></tr><tr><td rowspan=1 colspan=1>NormalEndemic</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.5 - 14.3</td><td rowspan=1 colspan=1>2.452</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>NormalNon-Endemic</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.6 - 8.9</td><td rowspan=1 colspan=1>2.002</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>ProspectiveStudy</td><td rowspan=1 colspan=1>523</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.1 - 22.2</td><td rowspan=1 colspan=1>4.409</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>10.9%</td></tr><tr><td rowspan=1 colspan=1>SensitivityStudy</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>0.9 - 40.4</td><td rowspan=1 colspan=1>7.994</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>71.1 %</td></tr></table>

Note: It is recommended that each laboratory determine its own normal range based on the population.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.